Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | SLC26A3 | P40879 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29271063 | 0.89 | AR (0.45) | KDM4EALDH1A1MAPTHPGDLOXL2 | |
| SCHEMBL22790797 | 0.86 | P2RY12 (0.60) | KDM4EALDH1A1MAPTHPGDLOXL2 | |
| SCHEMBL22787011 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1MAPTHPGDLOXL2 | |
| SCHEMBL31069854 | 0.77 | KDM4E (0.52) | KDM4EALDH1A1MAPTMAPK14POLB | |
| SCHEMBL31069855 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1MAPTLOXL2P2RY12 | |
| SCHEMBL7318349 | 0.75 | P2RY12 (0.78) | P2RY12PRKDC | |
| SCHEMBL22787008 | 0.72 | MAPT (0.55) | KDM4EALDH1A1MAPTHPGDEPHX2 | |
| SCHEMBL7316459 | 0.71 | P2RY12 (0.61) | KDM4EALDH1A1HPGDLOXL2P2RY12 | |
| SCHEMBL31635939 | 0.69 | AR (0.44) | KDM4EALDH1A1MAPTHPGDAR | |
| SCHEMBL7327157 | 0.68 | P2RY12 (0.63) | KDM4EALDH1A1HPGDLOXL2P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137355-A1 | PROXY BINDING FOR SCREENING THERAPEUTIC COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20240207413-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF C-MYC PROTEIN | NORTHWESTERN UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| WO-2020252398-A1 | PROTEOLYSIS-TARGETING PROTACS INDUCING DEGRADATION OF C-MIC PROTEIN | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200390894-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF C-MYC PROTEIN | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390894-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF C-MYC PROTEIN | MYCBP, MYC, MYCBP2 | KDM4E 1494/4885ALDH1A1 3786/4885MAPT 2474/4885 |
| US-20240207413-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF C-MYC PROTEIN | MYCBP, MYC, MYCBP2 | KDM4E 1494/4885ALDH1A1 3786/4885MAPT 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.